Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas.

Tabata T, Petitt M, Fang-Hoover J, Freed DC, Li F, An Z, Wang D, Fu TM, Pereira L.

Vaccines (Basel). 2019 Sep 29;7(4). pii: E135. doi: 10.3390/vaccines7040135.

2.

A Replication Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.

Liu Y, Freed DC, Li L, Tang A, Li F, Murray EM, Adler SP, McVoy MA, Rupp RE, Barrett D, Ye X, Zhang N, Beck K, Culp T, Das R, Song L, Vora K, Zhu H, Wang D, Espeseth AS, An Z, Musey L, Fu TM.

J Virol. 2019 Sep 11. pii: JVI.00747-19. doi: 10.1128/JVI.00747-19. [Epub ahead of print]

PMID:
31511385
3.

Identification of adipocyte plasma membrane-associated protein as a novel modulator of human cytomegalovirus infection.

Ye X, Gui X, Freed DC, Ku Z, Li L, Chen Y, Xiong W, Fan X, Su H, He X, Rustandi RR, Loughney JW, Ma N, Espeseth AS, Liu J, Zhu H, Wang D, Zhang N, Fu TM, An Z.

PLoS Pathog. 2019 Jul 29;15(7):e1007914. doi: 10.1371/journal.ppat.1007914. eCollection 2019 Jul.

4.

Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination.

Li F, Freed DC, Tang A, Rustandi RR, Troutman MC, Espeseth AS, Zhang N, An Z, McVoy M, Zhu H, Ha S, Wang D, Adler SP, Fu TM.

NPJ Vaccines. 2017 Dec 14;2:36. doi: 10.1038/s41541-017-0038-0. eCollection 2017.

5.

Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection.

Xia L, Tang A, Meng W, Freed DC, He L, Wang D, Li F, Li L, Xiong W, Gui X, Schultz RD, Chen H, He X, Swoyer R, Ha S, Liu Y, Morris CD, Zhou Y, Wang IM, Zhao Q, Luo W, Xia N, Espeseth AS, Hazuda DJ, Rupp RE, Barrett AD, Zhang N, Zhu J, Fu TM, An Z.

Oncotarget. 2017 Jun 3;8(43):73654-73669. doi: 10.18632/oncotarget.18359. eCollection 2017 Sep 26.

6.

Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody.

Meng W, Tang A, Ye X, Gui X, Li L, Fan X, Schultz RD, Freed DC, Ha S, Wang D, Zhang N, Fu TM, An Z.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01719-17. doi: 10.1128/AAC.01719-17. Print 2018 Jan.

7.

Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates.

Tang A, Freed DC, Li F, Meschino S, Prokop M, Bett A, Casimiro D, Wang D, Fu TM.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2763-2771. doi: 10.1080/21645515.2017.1308988. Epub 2017 May 11.

8.

Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.

Cui X, Freed DC, Wang D, Qiu P, Li F, Fu TM, Kauvar LM, McVoy MA.

J Virol. 2017 Jun 9;91(13). pii: e01650-16. doi: 10.1128/JVI.01650-16. Print 2017 Jul 1.

9.

Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.

Ha S, Li F, Troutman MC, Freed DC, Tang A, Loughney JW, Wang D, Wang IM, Vlasak J, Nickle DC, Rustandi RR, Hamm M, DePhillips PA, Zhang N, McLellan JS, Zhu H, Adler SP, McVoy MA, An Z, Fu TM.

J Virol. 2017 Mar 13;91(7). pii: e02033-16. doi: 10.1128/JVI.02033-16. Print 2017 Apr 1.

10.

A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.

Wang D, Freed DC, He X, Li F, Tang A, Cox KS, Dubey SA, Cole S, Medi MB, Liu Y, Xu J, Zhang ZQ, Finnefrock AC, Song L, Espeseth AS, Shiver JW, Casimiro DR, Fu TM.

Sci Transl Med. 2016 Oct 26;8(362):362ra145.

PMID:
27797961
11.

Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.

Finnefrock AC, Freed DC, Tang A, Li F, He X, Wu C, Nahas D, Wang D, Fu TM.

Hum Vaccin Immunother. 2016 Aug 2;12(8):2106-2112. Epub 2016 Mar 17.

12.

Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells.

Meng W, Li L, Xiong W, Fan X, Deng H, Bett AJ, Chen Z, Tang A, Cox KS, Joyce JG, Freed DC, Thoryk E, Fu TM, Casimiro DR, Zhang N, A Vora K, An Z.

MAbs. 2015;7(4):707-18. doi: 10.1080/19420862.2015.1051440.

13.

Soluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes.

Loughney JW, Rustandi RR, Wang D, Troutman MC, Dick LW Jr, Li G, Liu Z, Li F, Freed DC, Price CE, Hoang VM, Culp TD, DePhillips PA, Fu TM, Ha S.

J Biol Chem. 2015 Jun 26;290(26):15985-95. doi: 10.1074/jbc.M115.652230. Epub 2015 May 6.

14.

Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.

Freed DC, Tang Q, Tang A, Li F, He X, Huang Z, Meng W, Xia L, Finnefrock AC, Durr E, Espeseth AS, Casimiro DR, Zhang N, Shiver JW, Wang D, An Z, Fu TM.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4997-5005. doi: 10.1073/pnas.1316517110. Epub 2013 Dec 2.

15.

Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities.

Gray PM, Forrest G, Wisniewski T, Porter G, Freed DC, DeMartino JA, Zaller DM, Guo Z, Leone J, Fu TM, Vora KA.

Cell Immunol. 2012 Jul-Aug;278(1-2):113-9. doi: 10.1016/j.cellimm.2012.07.006. Epub 2012 Aug 4.

PMID:
23121983
16.

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.

Fu TM, Wang D, Freed DC, Tang A, Li F, He X, Cole S, Dubey S, Finnefrock AC, ter Meulen J, Shiver JW, Casimiro DR.

Vaccine. 2012 Dec 14;30(52):7469-74. doi: 10.1016/j.vaccine.2012.10.053. Epub 2012 Oct 26.

PMID:
23107592
17.

Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations.

Freed DC, Towne VM, Casimiro DR, Zhao Q, Fu TM.

Vaccine. 2011 Nov 21;29(50):9385-90. doi: 10.1016/j.vaccine.2011.09.122. Epub 2011 Oct 11.

PMID:
22001120
18.

Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.

Wang D, Li F, Freed DC, Finnefrock AC, Tang A, Grimes SN, Casimiro DR, Fu TM.

Vaccine. 2011 Nov 8;29(48):9075-80. doi: 10.1016/j.vaccine.2011.09.056. Epub 2011 Sep 22.

PMID:
21945962
19.

A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines.

Tang A, Li F, Freed DC, Finnefrock AC, Casimiro DR, Wang D, Fu TM.

Vaccine. 2011 Oct 26;29(46):8350-6. doi: 10.1016/j.vaccine.2011.08.086. Epub 2011 Aug 31.

PMID:
21888937
20.

Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge.

Casimiro DR, Cox K, Tang A, Sykes KJ, Feng M, Wang F, Bett A, Schleif WA, Liang X, Flynn J, Tobery TW, Wilson K, Finnefrock A, Huang L, Vitelli S, Lin J, Patel D, Davies ME, Heidecker GJ, Freed DC, Dubey S, O'Connor DH, Watkins DI, Zhang ZQ, Shiver JW.

J Virol. 2010 Mar;84(6):2996-3003. doi: 10.1128/JVI.00969-09. Epub 2009 Dec 30.

21.

Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization.

Katpally U, Fu TM, Freed DC, Casimiro DR, Smith TJ.

J Virol. 2009 Jul;83(14):7040-8. doi: 10.1128/JVI.00557-09. Epub 2009 Apr 29.

22.

Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys.

Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG.

Vaccine. 2009 Feb 25;27(9):1440-7. doi: 10.1016/j.vaccine.2008.12.034. Epub 2009 Jan 13.

PMID:
19146898
23.

PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination.

Finnefrock AC, Tang A, Li F, Freed DC, Feng M, Cox KS, Sykes KJ, Guare JP, Miller MD, Olsen DB, Hazuda DJ, Shiver JW, Casimiro DR, Fu TM.

J Immunol. 2009 Jan 15;182(2):980-7.

24.

Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus.

Fu TM, Freed DC, Horton MS, Fan J, Citron MP, Joyce JG, Garsky VM, Casimiro DR, Zhao Q, Shiver JW, Liang X.

Virology. 2009 Mar 1;385(1):218-26. doi: 10.1016/j.virol.2008.11.035. Epub 2008 Dec 13.

25.

Evaluation of cellular immune responses in subjects chronically infected with HIV type 1.

Fu TM, Dubey SA, Mehrotra DV, Freed DC, Trigona WL, Adams-Muhler L, Clair JH, Evans TG, Steigbigel R, Jacobson JM, Goepfert PA, Mulligan MJ, Kalams SA, Rinaldo C, Zhu L, Cox KS, Guan L, Long R, Persaud N, Caulfield MJ, Sadoff JC, Emini EA, Thaler S, Shiver JW.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):67-76.

PMID:
17263635
26.

A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects.

Tobery TW, Dubey SA, Anderson K, Freed DC, Cox KS, Lin J, Prokop MT, Sykes KJ, Mogg R, Mehrotra DV, Fu TM, Casimiro DR, Shiver JW.

AIDS Res Hum Retroviruses. 2006 Nov;22(11):1081-90.

PMID:
17147493
27.

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.

Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW, Davies ME, McDermott AB, O'Connor DH, Fridman A, Bagchi A, Tussey LG, Bett AJ, Finnefrock AC, Fu TM, Tang A, Wilson KA, Chen M, Perry HC, Heidecker GJ, Freed DC, Carella A, Punt KS, Sykes KJ, Huang L, Ausensi VI, Bachinsky M, Sadasivan-Nair U, Watkins DI, Emini EA, Shiver JW.

J Virol. 2005 Dec;79(24):15547-55.

28.

Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.

Bianchi E, Liang X, Ingallinella P, Finotto M, Chastain MA, Fan J, Fu TM, Song HC, Horton MS, Freed DC, Manger W, Wen E, Shi L, Ionescu R, Price C, Wenger M, Emini EA, Cortese R, Ciliberto G, Shiver JW, Pessi A.

J Virol. 2005 Jun;79(12):7380-8.

29.

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents.

Coplan PM, Gupta SB, Dubey SA, Pitisuttithum P, Nikas A, Mbewe B, Vardas E, Schechter M, Kallas EG, Freed DC, Fu TM, Mast CT, Puthavathana P, Kublin J, Brown Collins K, Chisi J, Pendame R, Thaler SJ, Gray G, Mcintyre J, Straus WL, Condra JH, Mehrotra DV, Guess HA, Emini EA, Shiver JW.

J Infect Dis. 2005 May 1;191(9):1427-34. Epub 2005 Mar 30.

PMID:
15809900
30.

Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene.

Casimiro DR, Tang A, Chen L, Fu TM, Evans RK, Davies ME, Freed DC, Hurni W, Aste-Amezaga JM, Guan L, Long R, Huang L, Harris V, Nawrocki DK, Mach H, Troutman RD, Isopi LA, Murthy KK, Rice K, Wilson KA, Volkin DB, Emini EA, Shiver JW.

J Virol. 2003 Jul;77(13):7663-8.

31.

Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW.

J Virol. 2003 Jun;77(11):6305-13.

32.

Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection.

Zhang ZQ, Fu TM, Casimiro DR, Davies ME, Liang X, Schleif WA, Handt L, Tussey L, Chen M, Tang A, Wilson KA, Trigona WL, Freed DC, Tan CY, Horton M, Emini EA, Shiver JW.

J Virol. 2002 Dec;76(24):12845-54.

33.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA.

Nature. 2002 Jan 17;415(6869):331-5.

PMID:
11797011
34.

Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.

Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, Davies ME, Shiver JW, Letvin NL.

J Immunol. 2002 Jan 15;168(2):562-8.

35.

Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.

Casimiro DR, Tang A, Perry HC, Long RS, Chen M, Heidecker GJ, Davies ME, Freed DC, Persaud NV, Dubey S, Smith JG, Havlir D, Richman D, Chastain MA, Simon AJ, Fu TM, Emini EA, Shiver JW.

J Virol. 2002 Jan;76(1):185-94.

36.

Evaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian/human immunodeficiency virus.

Fu TM, Freed DC, Trigona WL, Guan L, Zhu L, Long R, Persaud NV, Manson K, Dubey S, Shiver JW.

J Virol. 2001 Jan;75(1):73-82.

37.

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL.

Science. 2000 Oct 20;290(5491):486-92.

38.

Role of APC in the selection of immunodominant T cell epitopes.

Ma C, Whiteley PE, Cameron PM, Freed DC, Pressey A, Chen SL, Garni-Wagner B, Fang C, Zaller DM, Wicker LS, Blum JS.

J Immunol. 1999 Dec 15;163(12):6413-23.

39.

Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein.

Liang X, Munshi S, Shendure J, Mark G 3rd, Davies ME, Freed DC, Montefiori DC, Shiver JW.

Vaccine. 1999 Jul 16;17(22):2862-72.

PMID:
10438057
40.

Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration.

Barouch DH, Santra S, Steenbeke TD, Zheng XX, Perry HC, Davies ME, Freed DC, Craiu A, Strom TB, Shiver JW, Letvin NL.

J Immunol. 1998 Aug 15;161(4):1875-82.

41.

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

Letvin NL, Montefiori DC, Yasutomi Y, Perry HC, Davies ME, Lekutis C, Alroy M, Freed DC, Lord CI, Handt LK, Liu MA, Shiver JW.

Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9378-83.

42.

Anti-HIV env immunities elicited by nucleic acid vaccines.

Shiver JW, Davies ME, Yasutomi Y, Perry HC, Freed DC, Letvin NL, Liu MA.

Vaccine. 1997 Jun;15(8):884-7.

PMID:
9234539
43.

Humoral and cellular immunities elicited by HIV-1 vaccination.

Shiver JW, Davies ME, Perry HC, Freed DC, Liu MA.

J Pharm Sci. 1996 Dec;85(12):1317-24.

PMID:
8961146
44.

Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class II allele, DRB1*0401.

Wicker LS, Chen SL, Nepom GT, Elliott JF, Freed DC, Bansal A, Zheng S, Herman A, Lernmark A, Zaller DM, Peterson LB, Rothbard JB, Cummings R, Whiteley PJ.

J Clin Invest. 1996 Dec 1;98(11):2597-603.

45.

Vaccination of mice and nonhuman primates using HIV-gene-containing DNA.

Liu MA, Yasutomi Y, Davies ME, Perry HC, Freed DC, Letvin NL, Shiver JW.

Antibiot Chemother (1971). 1996;48:100-4. No abstract available.

PMID:
8726511
46.

Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.

Shiver JW, Perry HC, Davies ME, Freed DC, Liu MA.

Ann N Y Acad Sci. 1995 Nov 27;772:198-208.

PMID:
8546393
47.

T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.

Morkowski S, Goldrath AW, Eastman S, Ramachandra L, Freed DC, Whiteley P, Rudensky AYu.

J Exp Med. 1995 Nov 1;182(5):1403-13.

48.

Responses of NOD congenic mice to a glutamic acid decarboxylase-derived peptide.

Chen SL, Whiteley PJ, Freed DC, Rothbard JB, Peterson LB, Wicker LS.

J Autoimmun. 1994 Oct;7(5):635-41.

PMID:
7840855

Supplemental Content

Loading ...
Support Center